Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2025-12-25 @ 1:43 AM
NCT ID:
NCT02453594
Eligibility Criteria:
Inclusion criteria:
* Relapsed or refractory de novo classical Hodgkin lymphoma
* Participant may have failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-SCT)
* Participant may have failed to achieve a response or progressed after treatment with brentuximab vedotin or may be brentuximab vedotin naïve
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Measurable disease
* Adequate organ function
Exclusion criteria:
* Diagnosis of immunosuppression or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication
* Prior monoclonal antibody within 4 weeks prior to study Day 1 or chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to study Day 1
* Prior allogeneic hematopoietic stem cell transplantation
* Known clinically active central nervous system involvement
* Known additional malignancy that is progressing or requires active treatment
* Has a known history of Human Immunodeficiency Virus (HIV)
* Has known active Hepatitis B (HBV) or Hepatitis C (HCV)
* Active autoimmune disease requiring systemic treatment in past 2 years
* Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02453594
Study Brief:
Protocol Section:
NCT02453594